Cosentyx has posted solid, if unspectacular, sales growth in recent times but Novartis AG's flagship immunology product has made a stellar return, helped in no small part by its recent approval for hidradenitis suppurativa (HS).
Cosentyx Delivers Again For Novartis With Hidradenitis Suppurativa Launch
Two older drugs – Cosentyx and Entresto – continue to drive growth at the Swiss giant, while Leqvio is finally making its mark on the sales front.
More from Earnings
More from Business
• By
Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.